Results 1 to 10 of about 88,713 (223)

Amphotericin-B in dermatology

open access: yesIndian Dermatology Online Journal, 2022
Akash Agarwal, Bikash R Kar
doaj   +3 more sources

Amphotericin B Revisited

open access: yesMAMC Journal of Medical Sciences, 2021
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six decades. In light of the recent outbreak of mucormycosis (black fungus) cases during the second coronavirus disease 2019 wave in India, the relevance of ...
Sahil Kumar, Vandana Roy
doaj   +1 more source

Amphotericin B induced pancytopenia

open access: yesJournal of Family Medicine and Primary Care, 2022
Amphotericin B (AMB) has been the irreplaceable drug of choice for countless fungal and protozoal infections. One of the lesser-known adverse effects of AMB is Pancytopenia - very rare with very few cases reported - most commonly observed following ...
Esha Vaish   +3 more
doaj   +1 more source

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

open access: yesJournal of Fungi, 2020
As the oldest and for many decades the only available agent for the treatment of life-threatening invasive fungal diseases, amphotericin B (AmB) is known for its broad-spectrum fungicidal activity against a wide range of yeasts and molds.
Maria Aigner, Cornelia Lass-Flörl
doaj   +1 more source

An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety. [PDF]

open access: yesPLoS ONE, 2016
Amphotericin B is the most potent antimycotic known to date. However due to its large collateral toxicity, its use, although long standing, had been limited. Many attempts have been made to produce derivatives with reduced collateral damage.
Armando Antillón   +21 more
doaj   +1 more source

Identifying genetic variants associated with amphotericin B (AMB) resistance in Aspergillus fumigatus via k-mer-based GWAS

open access: yesFrontiers in Genetics, 2023
Aspergillus fumigatus is one of the most common pathogenic fungi, which results in high morbidity and mortality in immunocompromised patients. Amphotericin B (AMB) is used as the core drug for the treatment of triazole-resistant A. fumigatus.
Meng-Meng Chen   +7 more
doaj   +1 more source

Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B. [PDF]

open access: yesPLoS ONE, 2014
The polyene antifungal agent Amphotericin B exhibits potent and broad spectrum fungicidal activity. However, high nephrotoxicity can hinder its administration in resource poor settings.
Dithi Banerjee   +2 more
doaj   +1 more source

Comparative pharmacokinetics of amphotericin B after single- and multiple-dose administration of G-ABCD and conventional amphotericin B deoxycholate to rats

open access: yesJournal of Global Antimicrobial Resistance, 2020
Objective: G-ABCD is a biosimilar product of amphotericin B colloidal dispersion (ABCD). This study was designed to systematically examine the plasma pharmacokinetics (PK) and tissue distribution of G-ABCD in rats, using amphotericin B deoxycholate (DAmB)
Huanhuan Qi   +6 more
doaj   +1 more source

Lipase-Responsive Amphotericin B Loaded PCL Nanoparticles for Antifungal Therapies

open access: yesNanomaterials, 2022
Amphotericin B is an antifungal drug used for the treatment of invasive fungal infections. However, its clinical use is limited due to its serious side effects, such as renal and cardiovascular toxicity.
Evelyn Osehontue Uroro   +3 more
doaj   +1 more source

Therapeutic Drug Monitoring of Amphotericin-B in Plasma and Peritoneal Fluid of Pediatric Patients after Liver Transplantation: A Case Series

open access: yesAntibiotics, 2022
Fungal infections represent a serious complication during the post-liver transplantation period. Abdominal infections can occur following pre-existing colonization, surgical procedures, and permanence of abdominal tubes.
Francesca Tortora   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy